Search

Displaying results 4001 - 4010 of 10000 in total
  1. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  2. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987.

  3. Drug

    Telbivudine

    go.drugbank.com/drugs/DB01265
    ApprovedWithdrawn

    Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.

    Products: Sebivo Tablet 600mg
  4. Drug

    Argatroban

    go.drugbank.com/drugs/DB00278
    ApprovedInvestigational

    Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary

  5. Drug

    Danoprevir

    go.drugbank.com/drugs/DB11779
    Investigational

    Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

  6. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

  7. Drug

    Lonoctocog alfa

    go.drugbank.com/drugs/DB13998
    ApprovedInvestigational

  8. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of

  9. Drug

    Dexanabinol

    go.drugbank.com/drugs/DB06444
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    SCV-07 has shown efficacy in treating various viral and bacterial infections. … In independent studies, treatment of tuberculosis with SCV-07 improved clearance of mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating